

CSW INDUSTRIALS, INC.
Reported by
ARMES JOSEPH B

FORM 4
(Statement of Changes in Beneficial Ownership)

Filed 10/15/24 for the Period Ending 10/15/24

Address 5420 LYNDON B. JOHNSON FREEWAY
 SUITE 500
 DALLAS, TX, 75240
Telephone (214) 884-3777
CIK 0001624794
Symbol CSW
Fiscal Year 03/31

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Armes Joseph B (Last) (First) (Middle) 5420 LYNDON B JOHNSON FWY, STE. 500 (Street) DALLAS, TX 75240-1007 (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol CSW INDUSTRIALS, INC. [CSWI]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chairman, President & CEO				
			3. Date of Earliest Transaction (MM/DD/YYYY) 10/15/2024									
			4. If Amendment, Date Original Filed (MM/DD/YYYY)					6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	Amount				
Common Stock	10/15/2024		S ⁽¹⁾			13	D	\$388.21 ⁽²⁾		52,685
Common Stock	10/15/2024		S ⁽¹⁾			27	D	\$389.79 ⁽³⁾		52,658
Common Stock	10/15/2024		S ⁽¹⁾			26	D	\$390.64 ⁽⁴⁾		52,632
Common Stock	10/15/2024		S ⁽¹⁾			89	D	\$392.02 ⁽⁵⁾		52,543
Common Stock	10/15/2024		S ⁽¹⁾			148	D	\$393.01 ⁽⁶⁾		52,395
Common Stock	10/15/2024		S ⁽¹⁾			668	D	\$393.85 ⁽⁷⁾		51,727
Common Stock	10/15/2024		S ⁽¹⁾			26	D	\$395.18 ⁽⁸⁾		51,701
Common Stock	10/15/2024		S ⁽¹⁾			3	D	\$395.92 ⁽⁹⁾		51,698
Common Stock										1,500
Common Stock										3,142

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Performance Rights	(10)								(10)	(10)	Common Stock	8,236		8,236	D
Performance Rights	(11)								(11)	(11)	Common Stock	12,422		12,422	D
Performance Rights	(12)								(12)	(12)	Common Stock	7,851		7,851	D
Performance Rights	(13)								(13)	(13)	Common Stock	27,559		27,559	D
Restricted Stock Units	(14)								(14)	(14)	Common Stock	19,685		19,685	D

Explanation of Responses:

(1) The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on November 17, 2023.

(2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$387.72 to \$388.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

(3) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$389.24 to \$390.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

(4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$390.27 to \$391.23, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

(5) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$391.44 to \$392.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

(6) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$392.45 to \$393.425, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

(7) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$393.48 to \$394.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

(8) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$394.81 to \$395.77, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

(9) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$395.90 to \$395.94, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

(10) Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2024 and ending on March 31, 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

(11) Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2023 and ending on March 31, 2026 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

(12) Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2022 and ending on March 31, 2025 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

(13) Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest in three equal amounts, at a rate between 0% and 200%, during three performance cycles ending on each of March 31, 2025, 2026, and 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

(14) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at vesting. 40% of the restricted stock units vest no earlier than April 26, 2025 upon the successful recruitment and hiring of a successor Chief Executive Officer; the remaining 60% vest upon the successful first employment anniversary of a successor Chief Executive Officer.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Armes Joseph B 5420 LYNDON B JOHNSON FWY STE. 500 DALLAS, TX 75240-1007	X		Chairman, President & CEO	

Signatures/s/Luke E. Alverson, Attorney in Fact10/15/2024**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.